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Predicting ligand biological activity is a key challenge in drug dis-
covery. Ligand-based statistical approaches are often hampered by
noise due to undersampling: the number of molecules known to be
active or inactive is vastly less than the number of possible chem-
ical features that might determine binding. We derive a statistical
framework inspired by random matrix theory and combine the frame-
work with high quality negative data to discover important chemical
differences between active and inactive molecules by disentangling
undersampling noise. Our model outperforms standard benchmarks
when tested against a set of novel and challenging retrospective
tests. We prospectively apply our model to the human muscarinic
acetylcholine receptor M1, finding 4 experimentally-confirmed novel
agonists that are chemically dissimilar to all known ligands. The hit
rate of our model is significantly higher than the state of the art. Our
model can be interpreted and visualized to offer novel chemical in-
sights about the molecular motifs that are synergistic or antagonistic
to M1 agonism, which we have prospectively experimentally verified.
F inding novel hits to a target receptor is an importantinitial step in the long process of drug discovery. Al-
though biochemical assays are increasingly high throughput,
an experiment-only strategy that attempts to screen chemical
space exhaustively remains intractable. To accelerate drug
discovery, computer-aided virtual screening strategies have
been developed in the literature over the last decades [1–5].
Structure-based approaches require knowledge of the receptor
structure and the binding site, and predict the binding free
energy by modelling protein-ligand interactions [6–8]. How-
ever, determining the receptor structure and parametrising
protein-ligand interactions are often challenging, and notwith-
standing those challenges it is still computationally intensive
to compute the protein-ligand binding free energy [9, 10].
Ligand-based methods sidestep the challenges of structure-
based approaches and only require a set of molecules that are
known to be active against a particular receptor or triggers
a particular phenotype [11, 12]. Those methods are built
on the hypotheses that the receptor binding site recognises
a specific set of chemical motifs in a molecule, and those
motifs can be uncovered from chemical motifs that are shared
between the known active molecules. Therefore an unknown
molecule is likely to be active if it also contains those common
chemical motifs, and inactive otherwise. Those chemical motifs
characterise the protein binding site and proteins can be related
based on the chemical similarity of their ligands [13, 14].
However, regardless of how one defines chemical motifs –
common strategies include using pharmacological intuitions
[16–18], enumerating all linear or circular fragments below
a certain size around every atom [18, 19], or unsupervised
learning [20] – a molecule has many motifs but only a few are
important for biological activity of a particular target. Unless
one fortuitously knows a priori which motifs are important for
a specific receptor and eliminate the other “nuisance” motifs,
with a finite amount of data the nuisance motifs could drown
out the motifs that are actually important for binding simply
by chance. This problem is all the more challenging as it is
often the confluence of different motifs, rather than a single
motif, that drives binding, yet correlations are known to be
especially sensitive to noise due to undersampling [21–23].
Pioneering advances in machine learning that infer the optimal
representation of molecules directly from data, e.g. refs [24–
27], do not resolve this undersampling problem as the available
data is usually significantly less than the number of parameters
in the model.
In this paper, we show that removing the noise arising from
statistical undersampling – having not enough samples com-
pared to the number of motifs – is needed to reveal chemical
differences between active (positive) and inactive (negative)
molecules and identify important chemical motifs that deter-
mines activity. We develop a statistical method based on ran-
dom matrix theory and use our model to prospectively discover
experimentally-confirmed novel agonists of human muscarinic
acetylcholine receptor M1 that are chemically dissimilar to
known ligands. Our model also compares favourably with the
prior art on retrospective benchmark tests. Importantly, we
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Target RMD (Eq. 3) Random matrix Naive Bayes Tanimoto SVM Graph Convolutions
MOR1 0.99± 0.001 0.91± 0.003 0.95± 0.003 0.91± 0.005 0.70± 0.01 0.93± 0.007
5-HT2B 0.93± 0.007 0.82± 0.005 0.85± 0.01 0.85± 0.008 0.67± 0.02 0.87± 0.01
ADRA2A 0.90± 0.01 0.75± 0.01 0.84± 0.009 0.77± 0.02 0.61± 0.03 0.90± 0.006
Histamine H1 0.97± 0.003 0.87± 0.005 0.94± 0.007 0.87± 0.008 0.65± 0.02 0.84± 0.01
CCR5 0.92± 0.007 0.89± 0.008 0.90± 0.006 0.86± 0.01 0.68± 0.02 0.91± 0.009
hERG 0.83± 0.02 0.51± 0.01 0.79± 0.01 0.66± 0.02 0.60± 0.02 0.71± 0.01
Table 1. The AUC of our method, RMD, outperforms the random matrix theory benchmark [15] as well the naive Bayes, Tanimonto similarity,
SVM and graph convolutional fingerprint methods.
can interpret the model to offer novel pharmacological insights
about the roles of different chemical motifs in determining
activity.
Our work significantly extends a random matrix framework
developed by some of us [15] by having an explicit statistical
model for the inactive set, prospective experiments on a ther-
apeutically relevant receptor and robust retrospective tests
with confirmed inactives, as well as offering new biochemical
hypotheses through model visualisation and interpretation.
To our knowledge this is the first prospective validation of the
random matrix methodology applied to drug discovery. Our
work also demonstrates the importance of high quality nega-
tive data and methodologies that clean and exploit negative
correlations.
Random matrix theory and chemical correlations
We focus on a popular set of descriptors used in chemoinfor-
matics. Molecular fingerprints are typically constructed by
first representing a molecule as a 2D molecular graph, and
then considering all possible bond paths (contiguous atoms
connected by chemical bonds) within the molecule. Only iden-
tical molecules would share the same bond paths, and similar
molecules share most bond paths, thus comparing bond paths
is a reasonable way to quantify chemical similarity. As the
set of all possible bond paths is vast, typically fingerprints
are defined by first considering bond paths that are within
some radius of every atom in the molecule, and then mapping
these bond paths to a bit string of defined length through a
hash function. Throughout this paper, we will use the 1024
bit Morgan 3 fingerprint [19] generated using the open-source
package rdkit [28].
To determine which bond paths are important for binding,
we need to determine which bond paths are correlated in their
presence/absence in the set of active molecules relative to
the set of inactive molecules. Principal component analysis
provides way to do that. Mathematically, each molecule can
be characterised as a binary vector of length p, fi ∈ Rp. The
ensemble of N+ active molecules can be arranged as a data
matrix R+ = [f1; f2 · · · fN+ ] ∈ RN+×p, and similarly R− can
be constructed from the N− inactive molecules. We rescale
the features such that the columns of R± have zero mean
and unit variance; columns with zero variance are removed.
Persistent correlations in bond paths can be identified from
the eigendecomposition of each sample covariance matrix
C± =
1
N±
RT±R± =
p∑
i=1
λ±i v±i ⊗ v±i , [1]
where {λ±i } are the eigenvalues and {v±i } are the eigenvectors.
Each eigenvector v±i identifies a particular combination of
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Fig. 1. The eigenvalue distribution of random molecules drawn from ChEMBL follows
the random matrix distribution. The histogram shows the eigenvalue distribution of
200 random molecules drawn from ChEMBL, and the red curve is the random matrix
distribution, Equation (2), for p = 1024 and N = 200.
the p bond paths which explains a fraction λi/
∑
i
λi of the
variance.
However, not all eigenvectors are equally important. The
question of discriminating signal from noise due to the un-
dersampling in the context of molecular fingerprints has been
discussed in the literature [15, 29, 30]. Under certain weak
assumptions, if entries in R± are random and drawn from
a Gaussian distribution with zero mean and unit variance,
the probability of C± having an eigenvalue λ is given by the
Marchenko–Pastur distribution [31]
ρ±(λ) =
√[
(1 +√γ±)2 − λ
]2
+
[
λ− (1−√γ±)2
]2
+
2piγ±λ
, [2]
where γ± = p/N± describes how well-sampled the dataset of
active or inactive molecules is, and (·)+ = max{·, 0}. Equa-
tion (2) provides a suitable null distribution – only eigen-
vectors with eigenvalues outside the Marcenko–Pastur dis-
tribution are statistically significant. In practice, as the
Marcenko–Pastur distribution is non-zero only in the region
λ ∈ [(1−√γ±)2, (1 +√γ±)2], only eigenvectors with an eigen-
value greater than (1 +√γ±)2 are significant. In other words,
for a less well-sampled dataset (γ± large), an eigenvector needs
to have a large eigenvalue, i.e. explains a lot of the variance in
the data, before one can believe that it is significant. The sta-
tistically significant orthonormal eigenvectors are orthogonal
chemical features that are relevant for binding. If there arem±
significant eigenvalues, then the linear space spanned by those
m± associated eigenvectors, V± = span{v±1 ,v±2 , · · ·v±m±}, is
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Fig. 2. Our random matrix model captures the statistics of M1 agonists and confirmed inactives from a historic campaign. The random matrix distribution (red curve) agrees
with the histogram of eigenvalues of the (A) active agonists and (B) confirmed inactives. (C) A classification model built using the statistically significant eigenvectors achieves
an accuracy of 98%.
the subspace of chemical feature space that causes binding/non-
binding to that particular receptor.
Intuitively, a molecule is likely to be active if it is chemically
similar to the set of known active molecules and dissimilar
to the set of known inactive molecules. We can capture this
intuition by requiring the molecule, represented as the Morgan
fingerprint u, to be close to the linear subspace V+ but far
from V−. Therefore, we should classify a molecule u as active
if
D(u,V+) < D(u,V−) + , [3]
where  is a tolerance parameter that captures the tradeoff
between false positive and false negative, and D(u,V±) =∣∣∣∣u−∑m±
i=1
[
v±i · (u− µ±)/σ±
]
v±i
∣∣∣∣
2 is the distance between
the vector u, translated by the mean of the active/inactive set
µ± and scaled by the variance σ±, to the linear subspace V±.
Equation (3) is the central result of this paper. It extends
the result of our previous work [15] by explicitly accounting for
the set of inactive molecules. This is important as the set of
molecules tested are often clustered around scaffolds, and those
scaffolds will appear as statistically significant eigenvectors re-
gardless of whether they are important for binding. Therefore,
one should focus only on correlations that are present in the
active but not in the inactive set, which is the interpretation
of Equation (3). Henceforth we will refer to Equation (3) as
the Random Matrix Discriminant (RMD).
Retrospective benchmarks
We first validate the random matrix distribution as a suitable
null hypothesis. Figure 1 shows that the eigenvalue distribu-
tion of 200 random molecules drawn from ChEMBL [32] indeed
agrees with the random matrix null distribution, Equation (2).
The Kolmogorov-Smirnov test statistic is D = 0.087, thus the
hypothesis that the eigenvalue distribution follows Equation
(2) cannot be rejected at the 0.95 confidence level. A small
number of eigenvalues are outside the threshold predicted by
Equation (2) because of two reasons: First, Equation (2) is
derived asymptotically in the limit p,n→∞ with p/n fixed,
thus there are finite size corrections that we neglected. Second,
Equation (2) describes the typical behaviour of random matri-
ces rather than extreme value distributions. [33] Nonetheless,
by analysing 10 batches of 200 random molecules drawn from
ChEMBL, we find that more than 95% of the total number of
eigenvalues are within the bound predicted by Equation (2),
thus Equation (2) is a suitable null hypothesis.
Following our previous study [15], we benchmark RMD
using the challenge of identifying ligands of human G-Protein
Coupled Receptors (GPCRs). We consider GPCRs where
there are more than 500 known active molecules in ChEMBL
and more than 150 inactive molecules from the internal Pfizer
database; we consider only structures that are already in the
public domain so that the dataset can be fully disclosed in
the Supplementary Information. A ligand is considered active
against a given target if its Ki, Kd, IC50, or EC50 is 1 µM
or less, and inactive otherwise. Our previous study [15] only
considered active molecules because confirmed inactives from
a “pharmacologically plausible” chemical space are difficult to
obtain from the literature. This study importantly benefits
from high quality negative data from proprietary historic high
throughput screening campaigns. All in all, 4 receptors – µ
opioid receptor (MOR1), serotonin receptor 2B (5-HT2B), α-
2A adrenergic receptor (ADRA2A) and histamine H1 receptor
– have sufficient number of disclosable confirmed inactives.
Table 1 shows that RMD outperforms the benchmark [15]
as well as the naive Bayes method and classification based on
the mean Tanimonto coefficient against active molecules in the
training set. The latter two methods are common chemoin-
formatics methods used in the industry. Our method takes
into account the mean and pairwise correlations of chemical
features in a noise-robust manner, thus a natural question to
ask is whether our method outperforms non-linear methods in
the literature that use higher order correlations. To make this
comparison, we focus on the Support Vector Machine (SVM)
with a cubic kernel (which accounts for third order correlations)
and the Graph Convolutional Neural Network fingerprint [26].
Table 1 also shows that RMD outperforms SVM as well as the
Graph Convolutions (implemented in the open-source package
DeepChem [34]). In all tests, the active and inactive sets are
randomly split into a training set (90%) and test set (10%).
The figure of merit that we consider is the area under curve
(AUC) of the receiver operating characteristic. The mean AUC
and standard error of the mean are estimated by analysing 10
random partitions. In the Supplemental Material we show that
our method also outperforms other common machine learning
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methods for the Avalon fingerprint, another descriptor based
on a handcrafted set of chemical features [17], showing that
the importance of cleaning undersampling noise is independent
of descriptor choice. The AUCs of the two fingerprints with
RMD are comparable, and we use the Morgan 3 fingerprint for
ease of directly interpreting the model in terms of correlations
between chemical fragments, c.f. Figure 4.
One looming question is whether RMD performs well be-
cause the chemical space probed by Pfizer is different to the
published literature on ChEMBL. To answer this question,
we search our database for a receptor system where there are
more that 500 active molecules and 150 inactive molecules.
The receptor system that fulfils those criteria is the chemokine
receptor type 5 (CCR5). Table 1 also shows that RMD works
equally well when the chemical space of both the active and
inactive molecules originate from the same source.
Thus far we have only considered GPCRs. However RMD is
agnostic as to whether the target is a GPCR or even a protein
receptor. To illustrate this point, Table 1 shows that RMD can
accurately predict binding to hERG, a potassium ion channel
that is an “anti-target” for drug discovery as binding can cause
cardiac arrest [35, 36]. Both the active and inactive data come
from internal screens. Following commonly used thresholds
for hERG activity [35, 36], we classify compounds with an
IC50 < 9µM as active and IC50 > 29.9µM as inactive.
Prospective discovery of novel human M1 agonists
We select the human muscarinic acetylcholine receptor M1
as a target to prospectively deploy our algorithm. The mus-
carinic acetylcholine receptors are members of the rhodopsin-
like GPCRs and regulate the functions of the central and
peripheral nervous system. Currently, drugs that target mus-
carinic receptors have been approved for the treatment of
chronic obstructive pulmonary disease, overactive bladder
and Sjogren’s syndrome [37, 38]. Gene knockout studies sug-
gest that the M1 agonists may ameliorate the symptoms of
Alzheimer’s disease and related cognitive disorders, as well as
ameliorate psychosis-like symptoms in Schizophrenia [37, 38].
We use data from a historic campaign to train our model.
In total, 5445 compounds were screened for agonist activity,
out of which 222 were active (EC50 < 1µM). It is apparent
that the number of molecules, even in an industrial campaign,
is small compared to the number of chemical features, thus
removing undersampling noise is essential. Figure 2A-B shows
that the eigenvalue distribution of the active and inactive set
follows Equation (2), save for a few statistically significant
eigenvectors. Figure 2C reassures the reader by showing the
classification accuracy of RMD on the historic data; as before
the data is partitioned into training/testing (90%/10%) sets.
The model is then deployed to screen the entire
e− Molecules database [39], a publicly accessible database of
5.9 million commercially available chemical compounds. We
select the top 150 molecules using RMD, the naive Bayes classi-
fier as well as by maximum Tanimoto similarity to training set,
and perform a prospective experimental test (see Methods).
Figure 3 shows that RMD discovered 4 novel agonists. The
closest structure in the training set by Tanimoto similarity
is shown in the insets of Figure 3. RMD has found active
molecules that are structurally dissimilar to molecules in the
training set, and can successfully hop between chemical scaf-
folds. In terms of Tanimoto similarity, none of the new agonist
10-12 10-10 10-8 10-6 10-4
[Compound]/M
0
10
20
30
40
50
60
70
80
90
%
 o
f 1
0µ
M
 C
ar
ba
ch
ol 
re
sp
on
se
Compound A (EC50 = 80.1 nM)
Compound B (EC50 = 80.8 nM)
Compound C (EC50 = 144 nM)
Compound D (EC50 = 300 nM)
Carbachol
N
OO
HN
EC50 = 80.8 nM
N
OO
HN
EC50 = 80.1 nM
Cl
N
N
N
O
O
O
N
N
NS
O
O
O
O
N
OO
N
N
N
N
OO
N
NH
N
O
N
N
O
O
O NH
N
N
O
O
O NH
A B
C D
EC50 = 300 nMEC50 = 144 nM
Fig. 3. The RMD model discovered 4 novel human M1 agonists. Top panel: the
measured dose-response curves for the novel agonists. Bottom panel: The molecular
structures of the agonists; the insets show the closest molecule in the training set by
Tanimoto coefficient.
we found has a Tanimoto coefficient greater than 0.41 to any
molecule in the training set – this level of (dis)similarity is the
same as two molecules randomly drawn from ZINC, a large
database often used in virtual screening [40].
The hit rate of RMD is also greater than common chemoin-
formatics methods. For comparison, the naive Bayes classifier
only discovered 2 novel agonists and the agonists predicted by
the Tanimoto classifier are all inactive. Moreover, the hit rate
of a typical high throughput screen is ∼ 0.01%− 0.14% [41],
thus our model performance is around almost 40-fold better
than the background hit rate. This finding corroborates the
results from the retrospective test, Table 1.
Model interpretation and visualisation
The ability of RMD to prospectively discover novel M1 agonists
that are chemically dissimilar to the training set motivates
us to unbox the model and interpret its “reasoning”. RMD
classifies molecules based on their distance from the linear
subspace spanned by motifs in the active set relative to the
inactive set. As such, an intuitive way to interpret the model
is to directly visualise the difference between the two linear
subspaces. We can operationalise this difference by defining
the following effective correlation matrix
A =
m+∑
i=1
v+i ⊗ v+i −
m−∑
i=1
v−i ⊗ v−i . [4]
A positive entry Aij denotes that motifs i and j are jointly and
positively contributing to binding, whereas a negative entry
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Fig. 4. Our model can be interpreted as a network of features, where each feature is an entry of the molecular fingerprint. The opacity of the nodes is proportional to the
difference in the number of times that feature is present in the active set relative to the inactive set; only the top 10 features are shown. Red (blue) edges correspond to a
positive (negative) correlation, and the width of the edges is proportional to the strength of the correlation.
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denotes that the motifs are jointly and negatively effecting
binding. A similar approach have been proposed in the context
of principal component analysis where the goal is to reveal the
contrast between two groups [42].
Figure 4 shows that the motif-motif correlation matrix (4)
can be visualised and interpreted as a network of chemical
fragments. Each motif is an entry of the molecular fingerprint.
Due to bit collision, multiple fragments can be assigned to the
same motif. Interestingly, the model identifies the carbamate
fragment (node 10 in Figure 4) as distinct and positively
correlated to the piperazine fragments (node 2), and puts them
together to form the new active molecules C and D (c.f. Figure
3). Crucially, the model is able to learn that a carbamate
with a ternary nitrogen is the relevant fragment, rather than
a 6-membered ring piperidine-N-carboxylate or 7-membered
ring azepane-N-carboxylate present in the training set. In
other words, the model interpolates between structures in the
training set by learning generalisable chemical features rather
than simply memorising the training data. Another trend that
the model extracts is the correlation between carbamate (node
10) and aromatic fragments (nodes 1 and 2), agreeing with
the heuristic in the literature that M1 agonists generally have
a hydrogen bond acceptor and a distal aromatic moiety [43].
The negative correlations are also chemically significant.
One interesting prediction is that although the aromatic nitro-
gen fragment (node 1) and the piperazine fragment (node 2)
are both overrepresented in the active molecules, having both
fragments is strongly detrimental to agonist activity. Intrigu-
ingly, the model does not predict a similar negative correlation
between the aromatic nitrogen fragment and the cognate piperi-
dine fragment, which is structurally identical to piperazine
except having one less nitrogen atom. This subtle prediction
of an activity difference between piperidine and piperazine is
ripe for experimental testing.
We search our internal database for pairs of molecules
that are neither used in model training nor testing nor in
the e− Molecules database, both containing an aromatic
nitrogen moiety, and are exactly the same except one has a
piperidine ring and the other has a piperazine ring. Those
“matched molecular pairs” [44] were experimentally tested
for M1 agonist activity. Note that none of those matched
molecular pairs are considered in the original model, thus this
is a completely independent out-of-sample validation of model
prediction. Figure 5 shows that in all cases, swapping the
piperazine motif for the piperidine motif leads to a significant
increase in activity. This confirms the strongly negative motif-
motif correlation that our model has picked up as well as
demonstrating how we can exploit this chemical insight to
introduce a small chemical modification to the molecule that
significantly increases binding affinity. The visualisation in
Figure 4, combined with insights on synthetic accessibility,
can provide ideas for de novo design.
Conclusion
We derived a statistical framework inspired by random matrix
theory for ligand biological activity prediction that discovers
important correlations between chemical features by disen-
tangling undersampling noise and subtracting the correlation
structure of the active compounds from the inactive com-
pounds. We showed that the model outperforms standard
benchmarks when tested against a set of challenging retro-
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Fig. 5. Prospective matched molecular pair analysis corroborates the significant
negative correlation between the piperazine and the the aromatic nitrogen motif that
the model predicts.
spective tests. We prospectively applied the model to the
human muscarinic acetylcholine receptor M1 and found 4
experimentally-confirmed novel agonists that are chemically
dissimilar to all known agonists. Moreover, we can visualise
and interpret the model to yield novel pharmacological insights.
Our method distills which combinations of chemical motifs are
positively/negatively responsible for binding to the receptor,
and predicts pairs of motifs of which each individual motif is
overrepresented in the active molecule (thus naively expected
to be important for binding) yet when occurred as a pair
are detrimental to binding. We experimentally validated the
pharmacological insights predicted by the model, showing how
one can exploit insights afforded by the model to make a small
chemical change to a molecule to evade those negative motif
pairs and drastically improving potency. A broader conclusion
of our study is the power of high-quality inactive data, which
allows the model to generate meaningful hypothesis about
motif combinations that lead to inactivity.
Methods
M1 agonist assay. Chinese hamster ovary (CHO) cells stably
expressing the human muscarinic 1 receptor were plated at a
density of 7,500 cells per well (50 µL per well) in black walled
clear bottomed 384-well plates and were incubated overnight
(20-24 hours) in a 37oC humidified incubator with 5% carbon
dioxide. Agonist activity was determined by measuring com-
pound stimulated changes in intracellular calcium levels using
a calcium sensitive dye. Prior to the start of the experiment
the medium was removed from the plates and 80 µL of Hanks
balanced salt solution (HBSS) containing HEPES (20 mM),
Calcium 5 dye (Molecular Devices, Sunnyvale, CA; Catalogue
Number R8186) and probenecid (1.25 mM) was added to each
well and the plate was returned to the incubator for 1 hour to
allow dye loading. For compound assessment in the agonist
format 10 µL of the compound solution was added to each
well by the FLIPR Tetra instrument (Molecular Devices, Sun-
nyvale, CA ) and the change in fluorescence from baseline over
a 60 second period (Ex 470-495 nM; Em 515-575 nM) was
measured.
Data and code availability. Active and inactive compounds for
MOR1, 5-HT2B, ADRA2A, histamine H1, and hERG, as well
as data from the prospective experiments on M1, are available
in the SI. The ode used to perform RMD analysis is on GitHub
(github.com/alphaleegroup/RandomMatrixDiscriminant).
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